P
81.17
0.39 (0.48%)
| 前收盘价格 | 80.78 |
| 收盘价格 | 79.41 |
| 成交量 | 1,083,041 |
| 平均成交量 (3个月) | 810,707 |
| 市值 | 4,391,808,512 |
| 价格/销量 (P/S) | 21.65 |
| 股市价格/股市净资产 (P/B) | 18.91 |
| 52周波幅 | |
| 利润日期 | 25 Feb 2025 - 3 Mar 2025 |
| 营业毛利率 | -50.07% |
| 营业利益率 (TTM) | -38.42% |
| 稀释每股收益 (EPS TTM) | -1.95 |
| 季度收入增长率 (YOY) | 66.30% |
| 总债务/股东权益 (D/E MRQ) | 34.26% |
| 流动比率 (MRQ) | 6.02 |
| 营业现金流 (OCF TTM) | -91.61 M |
| 杠杆自由现金流 (LFCF TTM) | -82.85 M |
| 资产报酬率 (ROA TTM) | -16.73% |
| 股东权益报酬率 (ROE TTM) | -37.02% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | PROCEPT BioRobotics Corporation | 看涨 | 看涨 |
AIStockmoo 评分
1.6
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.63 |
|
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.51% |
| 机构持股比例 | 86.70% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 112.00 (Wells Fargo, 37.98%) | 购买 |
| 中 | 105.00 (29.36%) | |
| 低 | 75.00 (Piper Sandler, -7.60%) | 购买 |
| 平均值 | 98.40 (21.23%) | |
| 总计 | 4 购买, 1 保留 | |
| 平均价格@调整类型 | 89.11 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Wells Fargo | 03 Dec 2024 | 112.00 (37.98%) | 购买 | 96.48 |
| Morgan Stanley | 02 Dec 2024 | 105.00 (29.36%) | 购买 | 96.11 |
| Jefferies | 14 Nov 2024 | 95.00 (17.04%) | 保留 | 85.91 |
| Truist Securities | 30 Oct 2024 | 105.00 (29.36%) | 购买 | 93.03 |
| Piper Sandler | 08 Oct 2024 | 75.00 (-7.60%) | 购买 | 74.00 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合